Oliver Technow Receives the 2025 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Oliver Technow, former Chief Executive Officer of BIOVECTRA, as the recipient of the 2025 Bloom Burton Award.
Technology, Biotechnology, Investment Banking, Health
2025-09-26 7:36 AM EDT | Bloom Burton & Co. Inc.
MustGrow Announces Grant of RSUs and DSUs
Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors of the Company authorized and approved the grant of a total of 1,660,315 deferred share units ("DSUs") and restricted share units ("RSUs") to certain directors, officers, and consultants of the Company, effective September 25, 2025. This grants of DSUs and
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-09-26 7:00 AM EDT | MustGrow Biologics Corp.
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 12, 2025 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors. Detailed voting results for the ele
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-25 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Envoy Medical Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - September 25, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,908,402 shares of its Class A common stock at a purchase price of $1.31 per share of Class A common stock. In addition, in a concurrent private plac
Biotechnology, Healthcare and Hospitals
2025-09-25 8:00 AM EDT | Envoy Medical, Inc.
Envoy Medical Advances Commercialization Planning for Breakthrough Hearing Device as FDA Clinical Trial Remains On Track
White Bear Lake, Minnesota--(Newsfile Corp. - September 24, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing
Biotechnology, Healthcare and Hospitals
2025-09-24 8:00 AM EDT | Envoy Medical, Inc.
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, announced today the peer-reviewed publication of independent preclinical data demonstrating the superiority of its lead antiviral cand
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-09-24 7:00 AM EDT | Theralase Technologies Inc.
Kneat Recognised as Leader in G2 Pharma and Biotech Fall 2025 Grid Reports
Limerick, Ireland--(Newsfile Corp. - September 24, 2025) - kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, has been awarded the top position in three of G2 Software Review's Fall 2025 Pharma and Biotech Software category reports. Kneat was recognized as: Leader in the Grid® Report for Pharma and Biotech
2025-09-24 6:37 AM EDT | kneat.com, inc
Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a strategic partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Texas. The partnership was hatched after the initial sale of 200 Venowave™ VW5 units that targeted patients th
Technology, Biotechnology, Health
2025-09-24 6:30 AM EDT | Therma Bright Inc.
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to ann
Biotechnology, Pharmaceuticals, Health
2025-09-23 12:22 PM EDT | Hemostemix Inc.
Neural's Partner Hanf.com Expands Retail Footprint with 17th Store Opening Near Munich
Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of its 17t
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-23 12:16 PM EDT | Neural Therapeutics Inc.
Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to share the interview of Dr. Amie Phinney, Defence's director, strategy & business advisor, with Ellis Martin on Money Talk Radio.
Biotechnology, Pharmaceuticals, Health
2025-09-23 9:15 AM EDT | Defence Therapeutics Inc.
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025
Biotechnology, Pharmaceuticals
2025-09-23 8:30 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-23 7:45 AM EDT | Phio Pharmaceuticals Corp.
Envoy Medical Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,908,402 shares of its Class A common stock at a purchase price of $1.31 per share of Class A common stock, in a registered direct offering priced at-the-market under Nasd
Biotechnology, Healthcare and Hospitals
2025-09-22 8:00 AM EDT | Envoy Medical, Inc.
BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction
Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.
Biotechnology, Pharmaceuticals, Health
2025-09-22 6:32 AM EDT | BioHarvest Sciences Inc.
Scryb Announces Upsize of Private Placement Following Strong Investor Demand
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") is pleased to announce that due to strong market demand, it intends to upsize its previously announced non-brokered private placement (the "Offering") to $1,500,000, or 15,000,000 units of the Company (each, a "Unit") at a price of $0.10 per Unit. Each Unit will consist of one common share (a "Common Share") and one half of one common share p
Biotechnology, Healthcare and Hospitals, Health
2025-09-19 6:59 PM EDT | Scryb Inc.
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information circular dated September 9, 2025 and related meeting materials of the Company (the "Meeting Materials") for use at the annual ge
Biotechnology, Pharmaceuticals, Health
2025-09-19 6:00 PM EDT | PreveCeutical Medical Inc.
Britannia Life Sciences Inc. Delays Closing of Debenture Offering
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") announced today that the closing of its previously announced non-brokered private placement offering of unsecured debentures (the "Debentures") for gross proceeds of up to CAD$10 million (the "Offering") will be delayed until September 30, 2025 or such other date as the Company and subscribers may agree. The Offering was initiall
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2025-09-19 5:00 PM EDT | Britannia Life Sciences Inc
Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company has presented a poster abstract on minimal residual disease ("MRD") during the 22nd International Myeloma Society Annual Meeting in Toronto, Canada. The abstract, titled "3D Telomere P
2025-09-19 8:30 AM EDT | Telo Genomics Corp.
Envoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology
White Bear Lake, Minnesota--(Newsfile Corp. - September 19, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that it has received an Issue Notification from the European Patent Office and has been granted European Patent No. 4338791 which became effective September 17, 2025. The newly issued European patent strengthens Envoy Medical's global patent portfolio followin
Biotechnology, Healthcare and Hospitals
2025-09-19 8:00 AM EDT | Envoy Medical, Inc.